The DiaSorin Group has always been active in the area of immunodiagnostics, a market segment that encompasses immunochemistry and infectious immunology and accounts for 23% of the IVD market.
Today DiaSorin is active also in the molecular diagnostics segment. Thanks to the launch of LIAISON® IAM analyzer, a fully automated platform, the Group provides its clients with an integrated solution to the nucleic acids tests in specialized infectious disease laboratories and in the area of onco-hematology (leukemia).
In the field of immunodiagnostics, the main clinical areas cover above all:
Even if at the moment DiaSorin assay menu doesn’t include allergy tests and autoimmune disease tests, it is unique among those available in the IVD sector for its breadth and ability to meet most of medium and large-sized laboratories needs.
In the area of infectious diseases, however, DiaSorin offers the most complete menu of specialty tests provided by a single supplier. The Group’s main clients are hospital laboratories, private clinical laboratories or laboratories that are part of surgery facilities. The market share of these three segments changes in each country, but generally hospital laboratories register a higher number of performed tests, while private clinical laboratories register a higher market share. Among DiaSorin’s clients there are blood transfusion centers where specific IVD tests are performed. In the last years, IVD industry consolidated its presence in terms of clients, and in this case as well the phenomenon changes in each country. In some areas, such as USA and Germany, where the main companies play dominant roles, the private clinical laboratories market is extremely concentrated while it is extremely fragmented in Italy and France.